(Date:5/15/2008)... AARP commends Governor Paterson,s leadership...nd transparency, ALBANY, N.Y., May 15 /PRNewswire...s a paramount interest in passing the Governor,s p...ss the undue influence that,pharmaceutical compani...,only consumers, pocket books but the treatment th...
(Date:5/15/2008)... , WASHINGTON, D.C. -- May 15, 2008 -- The Socie...s (SCAI) today announced that it will hold its 200...sars Palace, Las Vegas. The focused, collegial int... February or early March meeting time beginning in...s will be the premier interventional cardiology me...
(Date:5/15/2008)... OAKLAND, Calif., May 15 /PRNewswire-FirstCal...tion (the "Company") today announced that, on May,...tion Letter stating that,the Company,s requests fo...as been denied. The NASDAQ noted that the Company ...bility to achieve near term compliance with,the co...
(Date:5/15/2008)... PRINCETON, N.J., May 15 /PRNewswire-FirstCal...l stage pharmaceutical company committed to,discov...to treat viral,infections, reported unaudited fina...March 31, 2008. Pharmasset reported a net loss att... or ($0.57) per share for the,quarter ended March ...
Breaking Medicine News(10 mins):Health News:AARP Statement on Governor's Bill for Prescription Drug Marketing Reform and Transparency 2Health News:SCAI announces 2009 annual scientific sessions in Las Vegas 2Health News:WorldHeart Announces Possible Delisting Action by NASDAQ 2Health News:WorldHeart Announces Possible Delisting Action by NASDAQ 3Health News:Pharmasset Reports Financial Results for Quarter Ended March 31, 2008 2Health News:Pharmasset Reports Financial Results for Quarter Ended March 31, 2008 3Health News:Pharmasset Reports Financial Results for Quarter Ended March 31, 2008 4Health News:Pharmasset Reports Financial Results for Quarter Ended March 31, 2008 5Health News:Pharmasset Reports Financial Results for Quarter Ended March 31, 2008 6Health News:Pharmasset Reports Financial Results for Quarter Ended March 31, 2008 7Health News:Pharmasset Reports Financial Results for Quarter Ended March 31, 2008 8...es have shown inhaled corticosteroids can reduce t... patients experience.// However, results from a st...f Washington show otherwise. Researchers studied m...re prescribed inhaled corticosteroids for at least...
...hows an antiparasitic drug appears to help people ...solium.// Researchers speculated treatment with t...ht might help these patients reduce the number of ...d 120 patients with signs of the living parasite i...
...discovery could help give insight into a very dead...n the gene // that codes for the progesterone rece...e PGR had previously been linked to a higher ovari... cancer risk in women who carry it. Researchers us...
...es have shown inhaled corticosteroids can reduce t... patients experience.// However, results from a st...f Washington show otherwise. Researchers studied m...re prescribed inhaled corticosteroids for at least...
Other Medicine News:(Date:5/15/2008)...- First in human clinical data highlight safety pr...advanced solid tumors -, BRISBANE, Calif., May 15... held biopharmaceutical company developing novel c...ing its lead PARP inhibitor, BSI-201, will,be pres...ology annual,meeting in Chicago., Findings will b...
(Date:5/15/2008)...hase II Data Presented at ASCO Showed Acceptable T...e of Grade 3 and 4 Neuropathy, WOODCLIFF LAKE, N....motherapeutic agent eribulin mesylate (E7389) demo...on of women with locally advanced or metastatic,br...r Phase II clinical,trial. The study also suggests...
(Date:5/15/2008)... - Unprecedented amount of research reflects dep...rs worldwide to develop new treatments for ...y session to highlight impact of Zometa(R), the le...nts with early-stage breast cancer, - Four oral s...ontinuous, inhibitor of mTOR, including first resu...
(Date:5/15/2008)...od pressure reductions demonstrated in Blacks, His...tes and Obese Individuals, PARSIPPANY, N.J., May ... today that data presented at the American Society... Meeting (ASH 2008) in New,Orleans demonstrated th...ine and olmesartan medoxomil) safely and effective...
Breaking Medicine Technology:BiPar Sciences Announces Clinical Data Presentations on Lead PARP Inhibitor, BSI-201, at 40th American Society of Clinical Oncology Annual Meeting 2Eribulin Mesylate Demonstrated Anti-Tumor Activity in Heavily Pretreated Patients with Advanced Breast Cancer 2Eribulin Mesylate Demonstrated Anti-Tumor Activity in Heavily Pretreated Patients with Advanced Breast Cancer 3Strength and Innovation of Novartis Oncology Products and Pipeline With Potential to Improve Patient Treatment Demonstrated by More Than 170 Abstracts at ASCO Annual Meeting 2Strength and Innovation of Novartis Oncology Products and Pipeline With Potential to Improve Patient Treatment Demonstrated by More Than 170 Abstracts at ASCO Annual Meeting 3Strength and Innovation of Novartis Oncology Products and Pipeline With Potential to Improve Patient Treatment Demonstrated by More Than 170 Abstracts at ASCO Annual Meeting 4Strength and Innovation of Novartis Oncology Products and Pipeline With Potential to Improve Patient Treatment Demonstrated by More Than 170 Abstracts at ASCO Annual Meeting 5Strength and Innovation of Novartis Oncology Products and Pipeline With Potential to Improve Patient Treatment Demonstrated by More Than 170 Abstracts at ASCO Annual Meeting 6Strength and Innovation of Novartis Oncology Products and Pipeline With Potential to Improve Patient Treatment Demonstrated by More Than 170 Abstracts at ASCO Annual Meeting 7Strength and Innovation of Novartis Oncology Products and Pipeline With Potential to Improve Patient Treatment Demonstrated by More Than 170 Abstracts at ASCO Annual Meeting 8Strength and Innovation of Novartis Oncology Products and Pipeline With Potential to Improve Patient Treatment Demonstrated by More Than 170 Abstracts at ASCO Annual Meeting 9Strength and Innovation of Novartis Oncology Products and Pipeline With Potential to Improve Patient Treatment Demonstrated by More Than 170 Abstracts at ASCO Annual Meeting 10Azor(TM) Reduces Blood Pressure in Difficult to Treat Special Populations 2Azor(TM) Reduces Blood Pressure in Difficult to Treat Special Populations 3Azor(TM) Reduces Blood Pressure in Difficult to Treat Special Populations 4Azor(TM) Reduces Blood Pressure in Difficult to Treat Special Populations 5Azor(TM) Reduces Blood Pressure in Difficult to Treat Special Populations 6Azor(TM) Reduces Blood Pressure in Difficult to Treat Special Populations 7EAU Technologies Announces New Chairman of the Board and Board Leadership 5753 1EAU Technologies Announces New Chairman of the Board and Board Leadership 5753 2EAU Technologies Announces New Chairman of the Board and Board Leadership 5753 3EAU Technologies Announces New Chairman of the Board and Board Leadership 5753 4Phlo Affiliate Names Director Of Marketing 1720 1Phlo Affiliate Names Director Of Marketing 1720 2Cost Effectiveness Study Supports Use of EUFLEXXA 28TM 29 by Rheumatologists for Pain Relief in Patients with Knee Osteoarthritis 792 1Cost Effectiveness Study Supports Use of EUFLEXXA 28TM 29 by Rheumatologists for Pain Relief in Patients with Knee Osteoarthritis 792 2Cost Effectiveness Study Supports Use of EUFLEXXA 28TM 29 by Rheumatologists for Pain Relief in Patients with Knee Osteoarthritis 792 3Cost Effectiveness Study Supports Use of EUFLEXXA 28TM 29 by Rheumatologists for Pain Relief in Patients with Knee Osteoarthritis 792 4Researchers analyze domestic violence deaths 5752 1Researchers analyze domestic violence deaths 5752 2Researchers analyze domestic violence deaths 5752 3...harmaceuticals Inc.,(TSX: TLN) announced today tha...ial investigating ECO-4601 in advanced cancer,pati... American,Society of Clinical Oncology (ASCO) Annu...se escalation portion of the study, 14,patients (t...lioma), that had completed and not responded to th...
...res favorably with,the activity of mTOR inhibitors...Call/ - AEterna,Zentaris Inc. , a global biopharma...oncology, today announced that its partner,Keryx ...ase 1 and,Phase 2 results for perifosine, an oral ..., for the treatment of patients with,advanced sarc...
Other Medicine Technology:Thallion Announces Publication of ECO-4601 Phase I/II Clinical Data,at ASCO 2Thallion Announces Publication of ECO-4601 Phase I/II Clinical Data,at ASCO 3AEterna Zentaris Partner Keryx Presents Phase 1 and Phase 2 Results,for Anti-Cancer Compound Perifosine at ASCO Meeting 2AEterna Zentaris Partner Keryx Presents Phase 1 and Phase 2 Results,for Anti-Cancer Compound Perifosine at ASCO Meeting 3AEterna Zentaris Partner Keryx Presents Phase 1 and Phase 2 Results,for Anti-Cancer Compound Perifosine at ASCO Meeting 4Pefakit TAFI Calibrators and Controls
Plasma Control Level 2 - 1 ml
...loped to address hematology needs in today's chang...enance, closed-tube sampling, small sample require...in the modern hematology lab. New challenges have ...nagement, and simplification of data interpretatio...
Inquire
Medicine Products: